 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...118119120121122123124125126127128...143144» |
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab (clinicaltrials.gov) - May 11, 2016
P2, N=68, Active, not recruiting, Sponsor: University of Zurich
Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Nerlynx (neratinib) / Puma
Trial primary completion date, Metastases: Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - May 6, 2016
P1/2, N=22, Active, not recruiting, Sponsor: NSABP Foundation Inc
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Jun 2016
- |||||||||| Opdivo (nivolumab) / BMS
New P3 trial, Metastases: Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer (clinicaltrials.gov) - May 6, 2016
P3, N=120, Not yet recruiting, Sponsor: RTOG Foundation, Inc.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Metastases: A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC (clinicaltrials.gov) - May 4, 2016
P2, N=122, Completed, Sponsor: National Health Research Institutes, Taiwan
Trial primary completion date: Mar 2016 --> Jun 2016 Recruiting --> Completed | Trial primary completion date: Aug 2014 --> Dec 2013
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Metastases: A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma (clinicaltrials.gov) - May 4, 2016
P2, N=47, Completed, Sponsor: National Health Research Institutes, Taiwan
Recruiting --> Completed | Trial primary completion date: Aug 2014 --> Dec 2013 Recruiting --> Completed | Trial primary completion date: Mar 2011 --> Jul 2011
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Biomarker, Trial primary completion date, FDG PET, Metastases: Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - May 3, 2016
P=N/A, N=25, Recruiting, Sponsor: VU University Medical Center
Recruiting --> Completed | Trial primary completion date: Mar 2011 --> Jul 2011 Trial primary completion date: Jan 2016 --> Jan 2017
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, PD(L)-1 Biomarker, IO biomarker, Metastases: Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) (clinicaltrials.gov) - May 2, 2016
P3, N=466, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jan 2016 --> Jan 2017 Recruiting --> Active, not recruiting
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Apr 27, 2016
P3, N=490, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy (clinicaltrials.gov) - Apr 27, 2016
P2, N=60, Not yet recruiting, Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- || telisotuzumab (h224G11) / AbbVie
Trial primary completion date, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Apr 22, 2016
P1, N=124, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2016 --> Oct 2016
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Enrollment change, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 22, 2016
P1, N=33, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2016 --> Oct 2016 N=77 --> 33
- || Tabrecta (capmatinib) / Incyte, Novartis
Trial primary completion date, Combination therapy: Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy (clinicaltrials.gov) - Apr 21, 2016
P1/2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
N=77 --> 33 Trial primary completion date: Feb 2017 --> Jan 2018
- elgemtumab (LJM-716) / Novartis, MorphoSys
Trial primary completion date, Combination therapy, Metastases: Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients (clinicaltrials.gov) - Apr 21, 2016
P1/2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2017 --> Jan 2018 Trial primary completion date: Aug 2017 --> Aug 2018
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Kisqali (ribociclib) / Novartis
Trial primary completion date, Metastases: CETLEE011: Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck (clinicaltrials.gov) - Apr 19, 2016
P1, N=26, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
Trial primary completion date: Aug 2017 --> Aug 2018 Trial primary completion date: Sep 2016 --> Sep 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date: Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors (clinicaltrials.gov) - Apr 15, 2016
P2, N=4, Terminated, Sponsor: Cliniques universitaires Saint-Luc- Universit
Trial primary completion date: Sep 2016 --> Sep 2017 N=60 --> 4 | Recruiting --> Terminated | Trial primary completion date: May 2017 --> Nov 2015; due to poor recrutment
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Monotherapy, Metastases: SAKK 41/10: Cetuximab for Elderly Patients With mCRC (clinicaltrials.gov) - Apr 15, 2016
P2, N=24, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
N=60 --> 4 | Recruiting --> Terminated | Trial primary completion date: May 2017 --> Nov 2015; due to poor recrutment N=78 --> 24
- |||| cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment open, Metastases: Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (clinicaltrials.gov) - Apr 14, 2016
P2, N=80, Recruiting, Sponsor: Washington University School of Medicine
N=78 --> 24 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date: S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=140, Recruiting, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2016 --> Jun 2017
- Piqray (alpelisib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) (clinicaltrials.gov) - Apr 9, 2016
P1, N=18, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Nov 2016 --> Jun 2017 Trial primary completion date: Oct 2016 --> Oct 2017
- || napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Metastases: A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 7, 2016
P2, N=150, Recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Jun 2016 --> Dec 2016
- ||||| AlloStim (bioengineered allogeneic immune cells) / Immunovative
Trial initiation date, Trial primary completion date, Metastases: AlloStim (clinicaltrials.gov) - Apr 7, 2016
P2/3, N=450, Not yet recruiting, Sponsor: Immunovative Therapies, Ltd.
Trial primary completion date: Jun 2016 --> Dec 2016 Initiation date: Mar 2016 --> Dec 2016 | Trial primary completion date: Mar 2019 --> Dec 2018
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
Enrollment closed, Enrollment change, Metastases: S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 7, 2016
P2, N=106, Active, not recruiting, Sponsor: Southwest Oncology Group
Initiation date: Mar 2016 --> Dec 2016 | Trial primary completion date: Mar 2019 --> Dec 2018 Recruiting --> Active, not recruiting | N=78 --> 106
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Trial initiation date, Combination therapy, Metastases: Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer (clinicaltrials.gov) - Apr 1, 2016
P1, N=45, Recruiting, Sponsor: University of Chicago
Recruiting --> Active, not recruiting | N=78 --> 106 Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Jun 2015
- Votrient (pazopanib) / Novartis, BeiGene, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Mar 29, 2016
P1, N=33, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Jun 2015 Trial primary completion date: Jun 2016 --> Jul 2015
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: ATOM: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Mar 29, 2016
P2, N=120, Active, not recruiting, Sponsor: EPS Corporation
Trial primary completion date: Jun 2016 --> Jul 2015 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment closed: ATOM ES: Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Mar 29, 2016
P=N/A, N=100, Active, not recruiting, Sponsor: EPS Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial initiation date, Metastases: Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (clinicaltrials.gov) - Mar 29, 2016
P2, N=80, Not yet recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Initiation date: Jan 2016 --> Apr 2016
- |||| Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Enrollment change, Combination therapy, Metastases: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (clinicaltrials.gov) - Mar 25, 2016
P1/2, N=261, Recruiting, Sponsor: Pharmacyclics
Initiation date: Jan 2016 --> Apr 2016 Active, not recruiting --> Recruiting | N=189 --> 261
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) (clinicaltrials.gov) - Mar 24, 2016
P3, N=466, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Recruiting | N=189 --> 261 N=600 --> 466 | Trial primary completion date: May 2017 --> Jan 2017
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 24, 2016
P2, N=50, Recruiting, Sponsor: Huazhong University of Science and Technology
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 23, 2016
P2, N=169, Completed, Sponsor: Cheryl Pugh
N=600 --> 466 | Trial primary completion date: May 2017 --> Jan 2017 Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
New P2 trial: ACE-Lung: Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer (clinicaltrials.gov) - Mar 23, 2016
P2, N=170, Not yet recruiting, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Mar 19, 2016
P2, N=50, Recruiting, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Dec 2016
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date: Neo-Adjuvant Study in Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Mar 19, 2016
P2, N=40, Active, not recruiting, Sponsor: The Methodist Hospital System
Trial primary completion date: May 2016 --> Dec 2016 Completed --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2016
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial, PD(L)-1 Biomarker, Surgery, Metastases: Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 18, 2016
P1/2, N=42, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tecentriq (atezolizumab) / Roche
Enrollment closed, PD(L)-1 Biomarker: RTOG 1216: Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (clinicaltrials.gov) - Mar 16, 2016
P2/3, N=675, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Completed --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2016 Recruiting --> Active, not recruiting
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: A Study in Head and Neck Cancer (clinicaltrials.gov) - Mar 16, 2016
P2, N=187, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 15, 2016
P1, N=77, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Feb 2017 --> Feb 2018
- | Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: PembroRad: Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC (clinicaltrials.gov) - Mar 14, 2016
P2, N=114, Not yet recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (clinicaltrials.gov) - Mar 10, 2016
P2, N=28, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: Dec 2016 --> Dec 2017
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial withdrawal, Metastases: Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study (clinicaltrials.gov) - Mar 9, 2016
P2, N=0, Withdrawn, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2016 --> Dec 2017 Terminated --> Withdrawn
- CGX1321 / Curegenix
Enrollment open, Combination therapy, Metastases: CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) (clinicaltrials.gov) - Mar 5, 2016
P1, N=86, Recruiting, Sponsor: Curegenix Inc.
Terminated --> Withdrawn Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Mar 5, 2016
P2, N=24, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=43 --> 24 | Trial primary completion date: Feb 2016 --> Mar 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Enrollment closed, Enrollment change, Metastases: PACER: A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 4, 2016
P2, N=52, Active, not recruiting, Sponsor: National Cancer Institute, Naples
Recruiting --> Active, not recruiting | N=43 --> 24 | Trial primary completion date: Feb 2016 --> Mar 2015 Recruiting --> Active, not recruiting | N=41 --> 52
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 27, 2016
P2, N=94, Completed, Sponsor: Eastern Cooperative Oncology Group
Recruiting --> Active, not recruiting | N=41 --> 52 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Surgery, Metastases: A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer (clinicaltrials.gov) - Feb 27, 2016
P=N/A, N=15, Completed, Sponsor: King Faisal Specialist Hospital & Research Center
Active, not recruiting --> Completed Recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date, Metastases: Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) (clinicaltrials.gov) - Feb 26, 2016
P2, N=0, Withdrawn, Sponsor: Centre Leon Berard
Recruiting --> Completed N=42 --> 0 | Initiation date: Jun 2015 --> Feb 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2017 --> Feb 2016
- ||| prexasertib (ACR-368) / Acrivon Therap
Enrollment open, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer (clinicaltrials.gov) - Feb 26, 2016
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
N=42 --> 0 | Initiation date: Jun 2015 --> Feb 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2017 --> Feb 2016 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial completion: Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients (clinicaltrials.gov) - Feb 23, 2016
P2, N=24, Completed, Sponsor: Foamix Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 21, 2016
P2, N=25, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2016 | Trial primary completion date: Jul 2018 --> Feb 2018